Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012

Venue: Grand Copthorne Waterfront Hotel

Location: Singapore, Singapore

Event Date/Time: Oct 15, 2012 End Date/Time: Oct 17, 2012
Early Registration Date: Aug 03, 2012
Report as Spam


Informa Life Sciences has over a decade-long experience in hosting Immunogenicity conferences in the US and Europe and is pleased to present the inaugural Immunogenicity for Biopharmaceuticals & Biosimilars Asia 2012. The ONLY event of its kind in the region, researched with and designed for the community of scientists driving progress and innovation in immunogenicity studies in the region. Bringing you global best practices and case studies, teamed with emerging local knowledge, this event will assist you in formulating solutions to your top immunogenicity challenges.

“Governments in Asia like Korea and Singapore,
have identified biopharmaceuticals as one of
the future engines for economic growth”
- ensure success in the design and commercialization of your biotherapies understanding, predicting and minimizing
the risk of immunogenic responses.

This comprehensive programme will provide you with a detailed insight to the immunogenicity field, including the underlying causes and implications of immunogenicity, current international developments and best practices in immunogenicity risk assessment, prediction, assay development and regulatory expectations and particular considerations for immunogenicity in the Asian region.

5 Reasons to Attend Asia Immunogenicity 2012:

The ONLY event of its kind in Asia - A ‘must attend’ event given the rapid development of the biotech industry in Asia
The region’s first to market event highlighting strategies for immunogenicity testing and critical advice to predict and manage unwanted immunogenicity
Immunogenicity is a major bottleneck in the discovery and development of biotherapeutics – Don’t miss this first event in Asia that will provide you with strategies to predict and manage the immunogenicity response
Bringing together a multidisciplinary audience this event will provide strategies from preclinical through to clinical to understand, predict and minimize the risk of an immunogenic response
Regulatory guidances for immunogenicity are unclear – Don’t miss your opportunity to hear a regulatory perspective about minimum data requirements for FDA/EU approval